Join the Keytruda group to help and get support from people like you.
Keytruda News
High Response to PD-1 Therapy Seen in Unresectable Desmoplastic Melanoma
TUESDAY, Aug. 19, 2025 – Patients with advanced desmoplastic melanoma have high response to single-agent anti-programmed death protein 1 (PD-1) therapy, according to a study published online Aug. 14...
Sustained Clinical Benefit Seen for Pembrolizumab + Axitinib in Advanced Renal Cancer
FRIDAY, Aug. 8, 2025 – For patients with advanced renal cell carcinoma (RCC), there is a sustained clinical benefit with pembrolizumab plus axitinib, according to a study published online Aug. 6 in...
An Artificial Sweetener May Hamper Immunotherapy Cancer Treatment
MONDAY, Aug. 4, 2025 — Findings from a study in mice suggest that using a common artificial sweetener, sucralose, could hamper certain immunotherapy treatments in cancer patients. However, for folks ...
Autoantibodies Influence Cancer Response To Immunotherapy, Study Says
MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoa...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 – The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those without health...
Insured? You're More Likely To Survive Cancer Through Immunotherapy Treatment
WEDNESDAY, July 9, 2025 — Powerful new immunotherapies are offering fresh hope for patients with many different types of cancer. Unfortunately, that hope doesn’t extend to people without health ins...
Clash Of Drugs Impedes Lung Cancer Treatment, Lowers Survival
TUESDAY, July 7, 2025 — Two drugs used in lung cancer treatment appear to be tripping over each other, reducing patients’ chances for a cure, a new study says. Corticosteroids are commonly prescribed ...
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 – For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly...
FDA Approves Keytruda (pembrolizumab) for PD-L1+ Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy
RAHWAY, N.J.--(BUSINESS WIRE) June 13, 2025 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
Outcomes With Immune Checkpoint Inhibitors Similar for Older, Younger Patients
TUESDAY, April 29, 2025 – Patients with cancer aged 65 years and older receiving immune checkpoint inhibitors (ICIs) derive similar clinical outcomes as younger patients, according to a study...
Immune Therapy Works As Well In Senior Cancer Patients As In Younger Adults
TUESDAY, April 22, 2025 — It’s well-known that a person’s immune system wears down over time, becoming less effective as folks progress through middle age and become seniors. But that doesn’t appear t...
Durable Disease Control Possible After Stopping Immune Checkpoint Inhibitors in NSCLC
TUESDAY, April 22, 2025 – Prolonged disease control can be maintained for patients with advanced non-small cell lung cancer (NSCLC) who discontinue immune checkpoint inhibitors (ICIs) for...
Lung Cancer Remains At Bay Long After Immune Therapy Is Dropped
MONDAY, April 21, 2025 — Immunotherapy might help keep lung cancer at bay for months or even years after the treatment has been abandoned due to side effects, a new study says. Immune checkpoint i...
FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1)
On March 19, 2025, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the...
TACE + Lenvatinib, Pembrolizumab Tied to Improved Survival in Unresectable Liver Cancer
THURSDAY, Jan. 16, 2025 – For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the addition of lenvatinib and pembrolizumab is...
Further information
Related condition support groups
Breast Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Hepatocellular Carcinoma, Hodgkin's Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Renal Cell Carcinoma